Should I buy or sell Aldeyra Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALDX shares. View ALDX analyst ratings or view top-rated stocks .

What is Aldeyra Therapeutics' stock price target for 2024?

3 brokerages have issued twelve-month price objectives for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $10.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 134.5% from the stock's current price. View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts .

How have ALDX shares performed in 2024?

Aldeyra Therapeutics' stock was trading at $3.51 at the start of the year. Since then, ALDX shares have increased by 13.4% and is now trading at $3.98. View the best growth stocks for 2024 here .

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,050,000 shares, an increase of 12.0% from the March 15th total of 1,830,000 shares. Based on an average trading volume of 585,700 shares, the days-to-cover ratio is presently 3.5 days. Approximately 3.6% of the shares of the company are sold short. View Aldeyra Therapeutics' Short Interest .

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALDX earnings forecast .

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) posted its quarterly earnings data on Thursday, March, 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.13.

What ETF holds Aldeyra Therapeutics' stock?

Invesco Nasdaq Future Gen 200 ETF holds 11,339 shares of ALDX stock, representing 0.63% of its portfolio.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Sorrento Therapeutics (SRNE) , KushCo (KSHB) , Bionano Genomics (BNGO) , Gran Tierra Energy (GTE) , Zosano Pharma (ZSAN) , Novan (NOVN) , Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI) .

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.65%), Woodstock Corp (0.29%) and Kingswood Wealth Advisors LLC (0.03%). Insiders that own company stock include Bruce Greenberg, Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady. View institutional ownership trends .

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALDX

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free ALDX Stock Alerts

$3.98

+0.01 (+0.25%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.89
▼
$4.07
50-Day Range: $2.77
▼
$4.72
52-Week Range: $1.42
▼
$11.97

Volume: 432,642 shs
Average Volume: 592,505 shs
Market Capitalization: $234.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.33

Get Aldeyra Therapeutics alerts:

Aldeyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 134.5% Upside
$9.33 Price Target
Short Interest: Healthy
3.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.65
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$1.47 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.14) to ($0.43) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.16 out of 5 stars

Medical Sector

532nd out of 918 stocks

Pharmaceutical Preparations Industry

231st out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Aldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.63% of the float of Aldeyra Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aldeyra Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aldeyra Therapeutics has recently increased by 12.02%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aldeyra Therapeutics does not currently pay a dividend.
Dividend Growth
Aldeyra Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALDX.

2.6

News and Social Media Coverage

News Sentiment
Aldeyra Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Aldeyra Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 18 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.
MarketBeat Follows
13 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aldeyra Therapeutics insiders have bought 303.41% more of their company's stock than they have sold. Specifically, they have bought $1,473,245.00 in company stock and sold $365,194.00 in company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Aldeyra Therapeutics is held by insiders.
Percentage Held by Institutions
59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aldeyra Therapeutics is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aldeyra Therapeutics is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aldeyra Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Aldeyra Therapeutics Stock (NASDAQ:ALDX)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

ALDX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALDX Stock News Headlines

April 9, 2024 | insidertrades.com

Perceptive Advisors Llc Purchases 37,712 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

April 4, 2024 | insidertrades.com

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Perceptive Advisors Llc Acquires 8,374 Shares

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 18, 2024 | businesswire.com

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

April 15, 2024 | markets.businessinsider.com

Attention Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors: Grabar Law Office Is Investigating Claims on Your Behalf

April 10, 2024 | investing.com

Perceptive advisors buys Aldeyra Therapeutics shares worth $833k

April 4, 2024 | msn.com

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

April 3, 2024 | msn.com

Aldeyra gains as Oppenheimer upgrades on revised plans for lead asset

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 3, 2024 | finance.yahoo.com

Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval

April 3, 2024 | finance.yahoo.com

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner

April 2, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)

March 13, 2024 | finance.yahoo.com

Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares

March 11, 2024 | markets.businessinsider.com

Strong Buy Rating for Aldeyra Therapeutics Backed by Reproxalap Developments and Strategic Partnerships

February 22, 2024 | finance.yahoo.com

Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company

February 14, 2024 | cnn.com

Intellia Therapeutics, Inc.

February 6, 2024 | finance.yahoo.com

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 31, 2024 | benzinga.com

Aldeyra Therapeutics Stock (NASDAQ:ALDX), Guidance and Forecast

January 28, 2024 | seekingalpha.com

Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects

January 4, 2024 | markets.businessinsider.com

Grabar Law Office Investigates Claims on Behalf of Shareholders of Aldeyra Therapeutics, Inc. (ALDX)

January 4, 2024 | finance.yahoo.com

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

December 31, 2023 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)

December 21, 2023 | markets.businessinsider.com

Outperform Rating Affirmed on Aldeyra Therapeutics Following Positive ADX Developments and Expanding Treatment Prospects

December 21, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Aldeyra Therapeutics Amidst Clinical Advancements and Market Potential

December 19, 2023 | msn.com

Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study

December 19, 2023 | marketwatch.com

Aldeyra Therapeutics Shares Rise 12% Following Positive Trial Results of ADX-629

December 19, 2023 | seekingalpha.com

Aldeyra stock jumps 8% on dermatitis drug updates

See More Headlines

Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALDX
CUSIP: N/A
CIK: 1341235
Web: www.ampliphibio.com
Phone: 781-761-4904
Fax: 781-270-0630
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.33
High Stock Price Target: $10.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +135.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,540,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -29.45%
Return on Assets: -24.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.64
Quick Ratio: 6.64

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.04 per share
Price / Book: 1.95

Miscellaneous

Outstanding Shares: 58,900,000
Free Float: 54,597,000
Market Cap: $233.83 million
Optionable: Optionable
Beta: 1.51

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Todd C. Brady (Age 48)
M.D., Ph.D., Chief Executive Officer and Director
Joshua Reed (Age 47)
Chief Financial Officer
David McMullin (Age 45)
Chief Commercial Officer
James A. Gow (Age 53)
M.D., Senior Vice President of Clinical Development
Stephen G. Machatha (Age 43)
Ph.D., Senior Vice President, Technical Operation

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALDX shares.
View ALDX analyst ratings or view top-rated stocks.
What is Aldeyra Therapeutics' stock price target for 2024?: 3 brokerages have issued twelve-month price objectives for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $10.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 134.5% from the stock's current price.
View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts.
How have ALDX shares performed in 2024?: Aldeyra Therapeutics' stock was trading at $3.51 at the start of the year. Since then, ALDX shares have increased by 13.4% and is now trading at $3.98.
View the best growth stocks for 2024 here.
Are investors shorting Aldeyra Therapeutics?: Aldeyra Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,050,000 shares, an increase of 12.0% from the March 15th total of 1,830,000 shares. Based on an average trading volume of 585,700 shares, the days-to-cover ratio is presently 3.5 days. Approximately 3.6% of the shares of the company are sold short.
View Aldeyra Therapeutics' Short Interest.
When is Aldeyra Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALDX earnings forecast.
How were Aldeyra Therapeutics' earnings last quarter?: Aldeyra Therapeutics, Inc (NASDAQ:ALDX) posted its quarterly earnings data on Thursday, March, 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.13.

What ETF holds Aldeyra Therapeutics' stock?: Invesco Nasdaq Future Gen 200 ETF holds 11,339 shares of ALDX stock, representing 0.63% of its portfolio.
What other stocks do shareholders of Aldeyra Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).
Who are Aldeyra Therapeutics' major shareholders?: Aldeyra Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.65%), Woodstock Corp (0.29%) and Kingswood Wealth Advisors LLC (0.03%). Insiders that own company stock include Bruce Greenberg, Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady.
View institutional ownership trends.
How do I buy shares of Aldeyra Therapeutics?: Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALDX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

Aldeyra Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Aldeyra Therapeutics Stock (NASDAQ:ALDX)

ALDX Stock Price History

ALDX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ALDX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™